Sanofi Forecast, price target & analysts
Sanofi Target price 2026 - Analyst rating & recommendation
Sanofi Classifications & Recommendation
Sanofi Price Target
| Target Price | €94.86 |
| Price | €71.52 |
| Potential |
32.63%
register free of charge
|
| Number of Estimates | 29 |
|
29 Analysts have issued a price target Sanofi 2027 .
The average Sanofi target price is €94.86.
This is
32.63%
register free of charge
€123.90
73.24%
register free of charge
€57.57
19.51%
register free of charge
|
|
| A rating was issued by 30 analysts: 17 Analysts recommend Sanofi to buy, 12 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sanofi stock has an average upside potential 2027 of
32.63%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion € | 46.72 | 49.50 |
| 5.49% | 5.97% | |
| EBITDA Margin | 24.56% | 31.04% |
| 3.19% | 26.39% | |
| Net Margin | 16.72% | 21.03% |
| 33.21% | 25.74% |
26 Analysts have issued a sales forecast Sanofi 2026 . The average Sanofi sales estimate is
This results in the following potential growth metrics:
21 Analysts have issued an Sanofi EBITDA forecast 2026. The average Sanofi EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
26 Sanofi Analysts have issued a net profit forecast 2026. The average Sanofi net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 6.37 | 8.69 |
| 44.12% | 36.42% | |
| P/E | 8.23 | |
| EV/Sales | 2.06 |
26 Analysts have issued a Sanofi forecast for earnings per share. The average Sanofi EPS is
This results in the following potential growth metrics and future valuations:
Current Sanofi Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ROTHSCHILD & CO REDBURN |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Sep 21 2026 |
| LEERINK PARTNERS |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Sep 04 2026 |
| INTESA SANPAOLO EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| TD COWEN |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| HSBC GLOBAL INVESTMENT RESEARCH |
Locked
➜
Locked
|
Locked | Aug 24 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
ROTHSCHILD & CO REDBURN:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Sep 21 2026 |
|
Locked
LEERINK PARTNERS:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Sep 04 2026 |
|
Locked
INTESA SANPAOLO EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
TD COWEN:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
HSBC GLOBAL INVESTMENT RESEARCH:
Locked
➜
Locked
|
Aug 24 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
